1. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects. Issue 3 (2nd October 2015) Authors: Lues, Inge; Weber, Frank; Meyer, Antje; Bühring, Uli; Hoffmann, Torsten; Kühn‐Wache, Kerstin; Manhart, Susanne; Heiser, Ulrich; Pokorny, Rolf; Chiesa, Joseph; Glund, Konrad Journal: Alzheimer's & dementia Issue: Volume 1:Issue 3(2015) Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. I19 Normalization of phenotype and reduction of gliosis levels via glutaminyl cyclases inhibition in a huntington disease mouse model. (September 2018) Authors: Plank, Anne-Christine; Schilling, Stephan; Hoffmann, Torsten; Lues, Inge; Hörsten, Stephan von Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89(2018)Supplement 1 Page Start: A95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O1‐10‐02: TOXIC PGLU‐ABETA IS ENHANCED AND GLUTAMINYL CYCLASE (QC) UP‐REGULATED EARLY IN ALZHEIMER'S DISEASE (AD): INHIBITORS OF QC BLOCKING PGLU‐ABETA FORMATION ARE IN CLINICAL DEVELOPMENT. (1st July 2014) Authors: Demuth, Hans‐Ulrich; Schilling, Stephan; Roßner, Steffen; Morawski, Markus; Hartlage‐Rübsamen, Maike; Lues, Inge; Glund, Konrad Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 1 Page Start: P149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1‐099: COMBINATION OF A GLUTAMINYL CYCLASE INHIBITOR (PQ912) AND A PYROGLUTAMATE‐Aβ SPECIFIC ANTIBODY (PBD‐M06) SHOWS ADDITIVE EFFECTS IN A MOUSE MODEL WITH ALZHEIMER'S DISEASE‐LIKE PATHOLOGY. (1st July 2006) Authors: Hoffmann, Torsten; Farcher, Martina; Hutter-Paier, Birgit; Lemere, Cynthia A.; Schilling, Stephan; Lues, Inge Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 5 Page Start: P309 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1–333: Safety, pharmacokinetics and pharmacodynamics of PQ912, the first glutaminyl cyclase (QC) inhibitor to treat Alzheimer's disease, in healthy elderly. (1st July 2013) Authors: Black, Ronald; Lues, Inge; Weber, Frank; Meyer, Antje; Hoffman, Torsten; Pokorny, Rolf; Demuth, Hans‐Ulrich; Glund, Konrad Journal: Alzheimer's & dementia Issue: Volume 9:Supplement 4S(2013)Part 7 Page Start: P280 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P3‐023: IN PURSUIT OF A SENSITIVE EEG FUNCTIONAL CONNECTIVITY OUTCOME MEASURE FOR CLINICAL TRIALS IN ALZHEIMER'S DISEASE. (1st July 2019) Authors: Briels, Casper T.; Stam, Cornelis J.; Scheltens, Philip; Bruins, Suzanne; Lues, Inge; Gouw, Alida A. Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7S(2019)Part 18 Page Start: P934 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗